1. Scrip
  2. >>Business

SERB Pays $800m For Boston Scientific Specialty Pharma Business

Device Maker Acquired The Drugs In $4.2bn BTG Buy Last Year

 
• By Reed Miller

The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.

Group of paper plane in one direction and with one individual pointing in the different way
Boston Scientific's sale of BTG Specialty Pharmaceuticals was anticipated when it bought BTG plc for $4.2bn • Source: Shutterstock

Stark International Lux SARL and SERB SAS, affiliates of Brussels-based SERB Specialty Pharmaceuticals, will pay $800m in cash for Boston Scientific's BTG Specialty Pharmaceuticals business. 

The deal announced on 1 December is worth about four times the business’s annual revenue and will close during the first half of 2021, subject to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.